The role of the herpes simplex virus (HSV)-encoded ribonucleotide reductase (RR) in the pathogenicity of the virus has been examined by use of mutants with lesions in either the large or small subunit of the enzyme. The virulence of the mutants in mice was reduced by about 106-fold when compared with that of the parental virus (HSV type 1 strain 17), while the virulence ofa revertant of one of the mutants was restored to within about 100-fold of that of the parent virus. These experiments demonstrate that activity of the HSV RR is essential for virus pathogenicity in mice and suggests that the enzyme is a valid target for specific antiviral compounds.
There are five well characterized human herpesviruses [herpes simplex virus types 1 and 2 (HSV-I and HSV-2), varicella zoster virus (VZV), human cytomegalovirus (HCMV) and Epstein-Barr virus (EBV)], all of which are important pathogens; a sixth, human B-lymphotrophic virus (HBLV) has recently been isolated from patients with acquired immune deficiency syndrome (Salahuddin et al., 1986) but as yet no definite disease has been associated with it. Apart from HBLV these herpesviruses have been shown to establish latent infections (reviewed by Wildy, 1985) . In the latent state the virus genome retains the potential to reactivate and produce both new lesions and infectious virus. To protect against virus infection vaccines are being developed, but this approach is at an early stage. Recently, the development of antiviral drugs, i.e. anti-metabolites which block virus-coded functions and hence interfere with production of infectious virus, has achieved some success. Particularly useful is acyclovir (ACV) which is converted through phosphorylation by the herpesvirus enzyme thymidine kinase to an antiviral nucleotide (Elion et al., 1977) . This compound interferes with viral DNA synthesis thereby preventing the production of infectious virus. The observation that ACV is not effective against HCMV (Balfour et al., 1982; Plotkin et al., 1982; Wade et al., 1982) emphasizes the need to produce antiviral drugs which exert their activity by a different mechanism.
Ribonucleotide reductase (RR) catalyses the reductive conversion of ribonucleotides to deoxyribonucleotides (Thelander & Reichard, 1979) . The HSV-1 enzyme consists of two subunits which we call RR~ and RR, (Cohen, 1972; Dutia, 1983; Preston et al., 1984; Frame et al., 1985 ; Cohen et al., 1985 ; Bacchetti et al., 1986) . The enzyme activity resides in a complex containing two molecules each of RRt and RR2 (Ingemarson & Lankinen, 1987) . We suggested (Frame et al., 1985) that disruption of the interaction between the two subunits might be a mechanism for anti-herpesvirus chemotherapy. This has found support from the discovery that a synthetic nonapeptide (YAGAVVNDL), corresponding to the carboxy-terminal nine amino acids of the small subunit, specifically inhibits the HSV-1 enzyme (Dutia et al., 1986 ; Cohen et 0000-8326 © 1988 SGM t The location of the subfragments a, b and c within plasmids pGX36 and pGX194 is shown in Fig. 1 .
al., 1986) by dissociation of the subunits (McClements et al., 1988) . Serological evidence for conservation of this carboxy-terminal region of the HSV-1 polypeptide in HSV-2, VZV, pseudorabies virus (PRV) and equine herpesvirus led to a suggestion that the nonapeptide might inhibit a broad range of herpesvirus RR enzymes (Dutia et al., 1986) . This idea is supported by the recent discovery that the PRV-induced enzyme is inhibited by the nonapeptide (Cohen et al., 1987) . These findings, together with the observation that the yield of a temperature-sensitive (ts) mutant with a lesion in the gene encoding RR1 was 100-fold less than that of parent virus in tissue culture at the non-permissive temperature (NPT) (Preston et al., 1984) , generated considerable interest in the exploitation of herpesvirus-specified RR as an antiviral target. However, two reports suggest that RR is not essential for virus growth in tissue culture. First, concentrations of hydroxyurea that inhibited RR activity to undetectable levels in proliferating cells infected with HSV-2 reduced virus yield by only sixfold (Nutter et al., 1985) . Second, an HSV-1 insertion mutant which lacks most of RR1 (including the region sharing homology with RR1 from other viruses) induces no detectable RR activity and produces only a four-to fivefold lower yield of progeny virus in exponentially gx'owing tissue culture cells than does the parent virus (Goldstein & Weller, 1988) . Furthermore, in our laboratory we have recently isolated a ts mutant, ts1222, which fails to induce detectable levels of RR activity at both permissive temperature (PT) and NPT (Preston et al., 1988) . It is possible that under some conditions the cellular enzyme might substitute for the virus enzyme. In view of these results it is important to investigate the role of HSV RR in the pathogenicity of the virus in animals. By the use of mutants with lesions in either RR1 or RR2 we now present data which show unambiguously that in mice the HSV RR is essential for pathogenicity,
The wild-type parent of the HSV-1 mutants ts1207 and ts1222 was the non-syncytial form (syn +) of strain 17 (Brown et al., 1973) . Mutant ts 1207 has a lesion within RR~ and fails to induce detectable levels of virus-specific enzyme activity at the NPT of 39-5 °C (Preston et al., 1984) . The mutation in this virus was derived from the multiple mutant tsG (Brown et al., 1983; Preston et al., 1984) . Marker rescue experiments (Table I) performed as described previously (Preston et al., 1984) revealed that ts1222 has a defect within the carboxy-terminal end of RR2 (Fig. 1 ). Cells infected with this virus at either 31 °C or the NPT exhibit no detectable virusspecific RR activity (Preston et al., 1988) . The spontaneous revertant ts ÷ 1222 rev 1, which is able to grow at the NPT and has RR activity, was obtained from a plaque-purified low passage stock of ts1222.
Virulence of 17syn +, mutants ts1207 and ts 1222, and the revertant of ts 1222 was determined in albino Charles River mice (15 g The open boxes on the mRNAs denote the translated portion of each transcript. The ts1222 lesion was located in the virus genome by marker rescue. The plasmid pGX36, which contains HSV-1 strain 17 BamHI o fragment inserted into the BamHI site of pAT153, was digested with BstEII and EcoRI, and the separated fragments were screened for the ability to rescue ts1222. The lesion mapped in fragment c, spanning the carboxy-terminal portion of RR2. The map position was refined using pGX194, a HindIII-BamHI subelone of pGX36. Fragment b from pGXI94 digested with HindIII, HincII and ScaI rescued the mutant. The lesion is therefore located between the BstEII site and the HincII site as denoted by the hatched box. Dotted horizontal lines represent plasmid vector sequences. The location of ts1207 was obtained previously (Preston et al., 1984) .
ear, and the left eye to the right ear. Other mice were inoculated with 200 gl of virus suspension directly into the peritoneal cavity. The mice were inoculated in groups of five, with selected dilutions of stock virus suspensions containing a known number of p.f.u, per ml. The relative numbers of mice in each challenge group alive or dead 91 days after inoculation were used to calculate the LDs0 dose for each virus by logit transformation of the dose-response curves (Litchfield & Wilcoxon, 1949) . The weights of the various groups were recorded at regular intervals up to 21 days to look for changes in the overall health status of the animals. The mean time of death for animals dying in the various challenge groups was also recorded. The majority of deaths occurred within 12 days of inoculation and for both the i.c. and i.p. routes the mean times to death recorded was indirectly proportional to the numbers of virus particles injected. Groups of mice in which there were no deaths showed weight gains indistinguishable from normal mice. Groups in which some mice died initially showed lower weight gains; however, after the death of all sick animals the survivors put on weight at a rate similar to normal mice. 
